Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yuejuan Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4491-2370; OpenAlex author ID A5060070844. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 20

  1. Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Stud… Co-author DOI 10.1002/mco2.70829↗
  2. Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. Co-author DOI 10.1038/s41392-026-02741-1↗
  3. Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. Co-author DOI 10.1177/17588359261470681↗
  4. Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report. Co-author DOI 10.21037/cco-2025-aw-132↗
  5. Comparison of Perfusion CT and Conventional Thin-slice Multiphase CT in the Diagnosis of Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.acra.2025.03.049↗
  6. S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. Co-author DOI 10.1177/17588359251378698↗
  7. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
  8. The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s11764-023-01429-7↗
  9. Efficacy of color Doppler ultrasound and contrast-enhanced ultrasound in identifying vascular invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13244-024-01779-5↗
  10. Development and validation of a nomogram model based on pretreatment ultrasound and contrast-enhanced ultrasound to predict the efficacy of neoadjuvant chemoth… Co-author DOI 10.1186/s40644-024-00662-2↗
  11. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenoca… Co-author DOI 10.1186/s12885-023-11464-3↗
  12. Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0189↗
  13. Pancreatic ductal adenocarcinoma with synchronous and metachronous hepatic metastasis predicted by contrast-enhanced ultrasound. Co-author DOI 10.21037/qims-22-1132↗
  14. Predicting the Efficacy of Neoadjuvant Chemotherapy for Pancreatic Cancer Using Deep Learning of Contrast-Enhanced Ultrasound Videos. Co-author DOI 10.3390/diagnostics13132183↗
  15. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Co-author DOI 10.1016/j.neo.2022.100841↗
  16. Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/cmar.s307079↗
  17. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resecti… Co-author DOI 10.3389/fonc.2021.660215↗
  18. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. First author DOI 10.1016/j.ejrad.2019.02.009↗
  19. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. Co-author DOI 10.1016/j.pan.2019.01.023↗
  20. Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer. Co-author DOI 10.3881/j.issn.1000-503x.2017.04.016↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunmei Bai · 12 shared papers, 2017–2026 · strength 2.31
  2. Hui Jun Tang · 6 shared papers, 2022–2026 · strength 1.35
  3. Tingting You · 5 shared papers, 2023–2026 · strength 1.28
  4. Yingyi Wang · 3 shared papers, 2025–2026 · strength 0.88
  5. Menghua Dai · 5 shared papers, 2021–2024 · strength 0.78
  6. Yingyi Wang · 4 shared papers, 2022–2024 · strength 0.76
  7. Ke Lv · 4 shared papers, 2021–2024 · strength 0.64
  8. Junchao Guo · 3 shared papers, 2022–2024 · strength 0.49
  9. Taiping Zhang · 2 shared papers, 2022–2026 · strength 0.41
  10. Huadan Xue · 2 shared papers, 2019–2025 · strength 0.36
  11. Zhengyu Jin · 2 shared papers, 2019–2025 · strength 0.36
  12. Yuming Shao · 2 shared papers, 2023–2024 · strength 0.35
  13. Xiaoyi Yan · 2 shared papers, 2023–2024 · strength 0.35
  14. Xiaoting Ma · 1 shared paper, 2026 · strength 0.33
  15. Yi Ba · 1 shared paper, 2026 · strength 0.33
  16. Wan-Ying Jia · 2 shared papers, 2023–2024 · strength 0.33
  17. Dongfeng Song · 1 shared paper, 2026 · strength 0.29
  18. Hui Tang · 1 shared paper, 2026 · strength 0.29
  19. Qiang Xu · 2 shared papers, 2021–2025 · strength 0.29
  20. Jiangdong Qiu · 1 shared paper, 2026 · strength 0.26
  21. Wenhao Luo · 1 shared paper, 2026 · strength 0.26
  22. Hao Chen · 1 shared paper, 2026 · strength 0.26
  23. Zhe Cao · 1 shared paper, 2026 · strength 0.26
  24. Yupei Zhao · 1 shared paper, 2026 · strength 0.26
  25. Huanwen Wu · 1 shared paper, 2025 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.